| TTM
|
3/31/2026
|
3/31/2025
|
3/31/2024
|
3/31/2023
|
|
|---|---|---|---|---|---|
| Total Revenue
|
287,675 | 287,675 | 306,924 | 405,777 | 406,350 |
| Cost of Revenue
|
-172,558 | -172,558 | -174,333 | -216,614 | -214,156 |
|
Gross Profit
|
115,117 | 115,117 | 132,590 | 189,163 | 192,194 |
| Selling, General and Administrative Expenses
|
-62,217 | -62,217 | -70,733 | -74,394 | -68,074 |
|
Research and Development Expenses
|
-26,960 | -26,960 | -35,265 | -33,866 | -32,174 |
| Other Income/Expense, Operating
|
286 | 286 | 172 | 153 | 234 |
|
Operating Income/Expenses
|
-88,891 | -88,891 | -105,826 | -108,107 | -100,014 |
|
Total Operating Profit/Loss
|
26,226 | 26,226 | 26,764 | 81,056 | 92,180 |
| Total Net Finance Income/Expense
|
-4,826 | -4,826 | -4,530 | -2,759 | -1,327 |
| Net Investment Income
|
-1,648 | -1,648 | -3,860 | -3,327 | -1,927 |
| Irregular Income/Expenses
|
-1,857 | -1,857 | -7,898 | 0 | -- |
|
Non-Operating Income/Expenses, Total
|
-8,331 | -8,331 | -16,288 | -6,086 | -3,254 |
|
Pretax Income
|
17,893 | 17,893 | 10,476 | 74,972 | 88,925 |
|
Provision for Income Tax
|
-8,036 | -8,036 | -2,085 | -9,645 | -13,585 |
|
Net Income from Continuing Operations
|
9,857 | 9,857 | 8,391 | 65,327 | 75,340 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
9,857 | 9,857 | 8,391 | 65,327 | 75,340 |
|
Net Income after Non-Controlling/Minority Interests
|
9,857 | 9,857 | 8,391 | 65,327 | 75,340 |
|
Net Income Available to Common Stockholders
|
9,857 | 9,857 | 8,391 | 65,327 | 75,340 |
|
Diluted Net Income Available to Common Stockholders
|
9,857 | 9,857 | 8,391 | 65,327 | 75,340 |
|
Common Dividend per Share
|
-- | -- | -- | 50.00 | 52.00 |
| Basic EPS
|
8.65 | 8.65 | 7.36 | 57.35 | 66.12 |
| Diluted EPS
|
8.63 | 8.63 | 7.35 | 57.26 | 66.07 |
|
Basic Weighted Average Shares Outstanding
|
1,139.07 | 1,139.07 | 1,139.41 | 1,139.13 | 1,139.46 |
|
Diluted Weighted Average Shares Outstanding
|
1,142.70 | 1,142.70 | 1,142.03 | 1,140.80 | 1,140.36 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
22,219 | 22,219 | 14,906 | 77,473 | 90,075 |
|
EBITDA
|
43,726 | 43,726 | 33,945 | 93,223 | 104,667 |
|
Normalized EBITDA
|
46,629 | 46,629 | 41,223 | 94,448 | 105,682 |
|
Normalized Income
|
12,513.25 | 12,513.25 | 14,220.68 | 66,393.98 | 76,199.71 |
|
Total Unusual Items
|
2,903 | 2,903 | 7,278 | 1,225 | 1,015 |
3/31/2023 - 1/4/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade